Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
FY2025 at a glance

Sales up 19.6%, free cash flow down to $27.8M

XBRL, from each 10-K
RevenueStatements
$510.2M from $426.5M in FY2024
FY2016FY2025
Net incomeStatements
$146.9M from $197.7M in FY2024
FY2016FY2025
Free cash flowStatements
$27.8M from $110.4M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.60 from $0.81 in FY2024
FY2016FY2025
Operating marginStatements
37.5% from 32.6% in FY2024
FY2016FY2025
Total debtStatements
$72.1M from $72.3M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
0.77
Sales (ttm)
519.2M
Net income (ttm)
182.4M
Sales growth
+19.6%
EPS growth
-25.9%
Sales Q/Q
+5.1%
Free cash flow
132.9M
Gross margin
68.5%
Oper. margin
46.5%
Net margin
35.1%
FCF margin
25.6%
R&D / sales
0.9%
Dividend
-
Debt/Eq
0.45
Curr. ratio
6.04
Cash
124.6M
Op. cash flow (ttm)
140.8M
EBITDA
199.4M
EBITDA margin
39.1%
Net debt
71.3M
Quick ratio
3.88
Interest cover
26.93
ROIC
24.3%
FCF after stock pay
7.8M
Debt / FCF (years)
7.04
Goodwill / assets
0.6%
Oper. margin low 5y
-72.1%
Tax rate
19.6%
Stock pay / sales
3.9%
Shares out.
221.9M
Shares Y/Y
+0.6%
Book / share
1.98
Cash / share
0.56
Sales / share
2.34
Asset turnover
0.71
Inventory turns
1.05
Days sales out.
113
Sales 3Y CAGR
+49.0%
Sales 5Y CAGR
+64.6%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 510.2M +53.7% a year Net income 146.9M
FY2016 revenue 10.7M · Revenues, 0001193805-18-000470 FY2016 net income -19.5M · NetIncomeLoss, 0001193805-18-000470 10.7M FY2016 FY2017 revenue 22.8M · Revenues, 0001193805-19-000281 FY2017 net income -43.8M · NetIncomeLoss, 0001193805-19-000281 22.8M FY2017 FY2018 revenue 17.0M · Revenues, 0001193805-20-000348 FY2018 net income -65.7M · NetIncomeLoss, 0001193805-20-000348 17.0M FY2018 FY2019 revenue 29.3M · Revenues, 0001193805-21-000411 FY2019 net income -48.3M · NetIncomeLoss, 0001193805-21-000411 29.3M FY2019 FY2020 revenue 42.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-22-011030 FY2020 net income -75.7M · NetIncomeLoss, 0001140361-22-011030 42.2M FY2020 FY2021 revenue 80.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-24-010147 FY2021 net income -71.6M · NetIncomeLoss, 0001140361-24-010147 80.9M FY2021 FY2022 revenue 154.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-25-009257 FY2022 net income -65.9M · NetIncomeLoss, 0001140361-25-009257 154.1M FY2022 FY2023 revenue 258.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-26-006815 FY2023 net income -28.2M · NetIncomeLoss, 0001140361-26-006815 258.2M FY2023 FY2024 revenue 426.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-26-006815 FY2024 net income 197.7M · NetIncomeLoss, 0001140361-26-006815 426.5M FY2024 FY2025 revenue 510.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001140361-26-006815 FY2025 net income 146.9M · NetIncomeLoss, 0001140361-26-006815 510.2M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +13.7% a year FY2020 $1.02 to FY2025 $1.95, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.60$1.95$0.11
Dec 31, 2024 $0.81$1.43$0.45
Dec 31, 2023 -$0.13$0.60$0.02
Dec 31, 2022 -$0.33$0.77-$0.37
Dec 31, 2021 -$0.51$1.01-$0.90
Dec 31, 2020 -$0.88$1.02-$1.33
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $466.5M
  • − All liabilities $146.9M
  • = Net current asset value $319.6M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $477.3M
  • − Goodwill $3.5M
  • − Other intangible assets $632K
  • = Tangible book value $473.2M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ADMA against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+19.6%42nd of 155 · median +10.5%
Net margin
-4.1%15.3%
35.1%6th of 154 · median 6.8%
Return on equity
-5.2%18.5%
41.6%11th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
25.6%15th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.4530th of 108 · median 0.69
ADMA and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ADMA Adma Biologics, Inc.$519.2M +19.6%68.5%35.1%41.6%25.6%0.45
VCYT Veracyte, Inc.$581.8M +16.0%72.0%21.8%8.9%27.8%-
PTGX Protagonist Therapeutics, Inc$551.7M -89.4%-62.0%31.5%19.8%-
KRYS Krystal Biotech, Inc.$470.0M +33.9%-47.9%15.7%66.0%-
WGS GeneDx Holdings Corp.$460.8M +40.0%68.7%-24.1%-45.4%-22.0%0.61
ZLAB Zai Lab Ltd$441.7M +15.3%53.4%-44.9%-35.2%-37.0%0.45
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $426.5M of sales to $197.7M of profit FY2024

  • ADMA Bio Manufacturing $415.8M
  • Plasma Collection Centers $10.5M
Revenue to Gross profit: $219.6MRevenue to Cost of revenue: $206.9MGross profit to Operating profit: $139.0MGross profit to Operating expenses: $80.6MOperating profit to Net profit: $139.0MOther income to Net profit: $58.7MOperating expenses to R&D: $1.8MOperating expenses to Sales, admin & other: $78.8M Revenue: $426.5M REVENUE $426.5M +65% Y/Y Gross profit: $219.6M · 51% margin GROSS PROFIT $219.6M 51% margin · +147% Y/Y Cost of revenue: $206.9M · 49% of revenue COST OF REVENUE $206.9M 49% of revenue Operating profit: $139.0M · 33% margin OPERATING PROFIT $139.0M 33% margin · +542% Y/Y Other income: $58.7M · 14% of revenue OTHER INCOME $58.7M 14% of revenue Operating expenses: $80.6M · 19% of revenue OPERATING EXPENSES $80.6M 19% of revenue Net profit: $197.7M · 46% margin NET PROFIT $197.7M 46% margin R&D: $1.8M · 0% of revenue R&D $1.8M 0% of revenue Sales, admin & other: $78.8M · 18% of revenue SALES, ADMIN & OTHER $78.8M 18% of revenue

From $510.2M of sales to $146.9M of profit FY2025

  • ADMA Bio Manufacturing $493.0M
  • Plasma Collection Centers $17.0M
Revenue to Gross profit: $292.8MRevenue to Cost of revenue: $217.4MGross profit to Operating profit: $191.4MGross profit to Operating expenses: $101.3MOperating profit to Net profit: $146.9MOperating profit to Tax & other: $44.5MOperating expenses to R&D: $4.8MOperating expenses to Sales, admin & other: $96.6M Revenue: $510.2M REVENUE $510.2M +20% Y/Y Gross profit: $292.8M · 57% margin GROSS PROFIT $292.8M 57% margin · +33% Y/Y Cost of revenue: $217.4M · 43% of revenue COST OF REVENUE $217.4M 43% of revenue Operating profit: $191.4M · 38% margin OPERATING PROFIT $191.4M 38% margin · +38% Y/Y Operating expenses: $101.3M · 20% of revenue OPERATING EXPENSES $101.3M 20% of revenue Net profit: $146.9M · 29% margin NET PROFIT $146.9M 29% margin · −26% Y/Y Tax & other: $44.5M · 9% of revenue TAX & OTHER $44.5M 9% of revenue R&D: $4.8M · 1% of revenue R&D $4.8M 1% of revenue Sales, admin & other: $96.6M · 19% of revenue SALES, ADMIN & OTHER $96.6M 19% of revenue

Where each $100 of sales went

FY2024
FY2025
  • Cost of revenue
  • Sales, admin & other
  • Net profit
  • R&D
  • Tax & other

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 30.8% FY2020: -85.8% net income ÷ equity
Net margin 28.8% FY2020: -179.4% profit per $ of sales: 146.9M ÷ 510.2M
Asset turnover 0.82× FY2020: 0.20× sales per $ of assets: 510.2M ÷ 624.2M
Leverage 1.31× FY2020: 2.35× assets per $ of equity: 624.2M ÷ 477.3M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    35.1% vs 6.8%
  • Gross margin up over 5 years
    -45.2% → 57.4%
  • Return on equity above 15%
    41.6%
  • A profit in 2 of 10 years
Net margin, FY2016 to FY2025: -183.1% to 28.8%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 26.9× interest expense
  • Debt smaller than equity
    Debt / equity 0.45 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 6.04
  • Net debt under 3 years of free cash flow
    $71.3M net debt, 0.5 years
Debt / equity at each year end, FY2016 to FY2025: 0.07 to 0.15

Cash and shareholders

  • Free cash flow positive in 3 of 10 years
    $27.8M last year
  • Share count up over 5 years
    +184.3%
  • Cash from operations below net income
    $50.4M vs $146.9M
Free cash flow, FY2016 to FY2025: -18.3M to 27.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$196.2M of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities, current part

Paid in advance $143K cash received before delivery, not yet recognized as revenue, Jun 30, 2025 · -87.3% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ADMA's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue510.2M
FY2016: 10.7MFY2017: 22.8MFY2018: 17.0MFY2019: 29.3MFY2020: 42.2MFY2021: 80.9MFY2022: 154.1MFY2023: 258.2MFY2024: 426.5MFY2025: 510.2M FY2017FY2019FY2021FY2023FY2025
Net income146.9M
FY2016: -19.5MFY2017: -43.8MFY2018: -65.7MFY2019: -48.3MFY2020: -75.7MFY2021: -71.6MFY2022: -65.9MFY2023: -28.2MFY2024: 197.7MFY2025: 146.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow27.8M
FY2016: -18.3MFY2017: -39.9MFY2018: -64.8MFY2019: -80.0MFY2020: -114.7MFY2021: -125.9MFY2022: -73.4MFY2023: 4.0MFY2024: 110.4MFY2025: 27.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay7.8M
FY2016: -19.6MFY2017: -41.5MFY2018: -67.0MFY2019: -82.7MFY2020: -117.6MFY2021: -129.4MFY2022: -78.6MFY2023: -2.2MFY2024: 96.8MFY2025: 7.8M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.60
FY2016: -1.61FY2017: -1.91FY2018: -1.45FY2019: -0.89FY2020: -0.88FY2021: -0.51FY2022: -0.33FY2023: -0.13FY2024: 0.81FY2025: 0.60 FY2017FY2019FY2021FY2023FY2025
Diluted shares244.9M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 86.1MFY2021: 139.6MFY2022: 197.9MFY2023: 224.0MFY2024: 243.3MFY2025: 244.9M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
ADMA Bio Manufacturing 493.0M96.6% +18.6%
Plasma Collection Centers 17.0M3.3% +62.1%

10-K 0001140361-26-006815, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 503.9M98.8% +22.9%
Non Us 6.1M1.2% -62.6%

10-K 0001140361-26-006815, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
ADMA Bio Manufacturing74.9M144.1M249.7M415.8M493.0M
Plasma Collection Centers5.9M9.9M8.3M10.5M17.0M
Corporate143K143K143K--
Sum of segments80.8M153.9M258.1M426.3M510.0M

Operating income by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
ADMA Bio Manufacturing-29.3M879K47.5M--
Plasma Collection Centers-12.1M-17.9M-4.0M--
Corporate-17.0M-22.3M-21.8M--

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue10.7M22.8M17.0M29.3M42.2M80.9M154.1M258.2M426.5M510.2M
Cost of revenue1.6M29.2M42.2M39.5M61.3M79.8M118.8M169.3M206.9M217.4M
Gross profit4.3M-6.4M-25.2M--19.1M1.2M35.3M88.9M219.6M292.8M
R&D7.7M5.6M3.9M2.3M5.9M3.6M3.6M3.3M1.8M4.8M
SG&A8.5M18.8M22.5M25.9M35.1M42.9M52.5M59.0M74.1M91.6M
Operating income-17.3M-39.3M-60.3M-41.4M-64.9M-58.4M-39.4M21.6M139.0M191.4M
Interest expense2.2M3.3M5.5M9.0M12.0M13.1M19.3M25.0M13.9M7.1M
Pretax income-19.5M------65.9M-28.2M125.7M182.7M
Income tax00000000-72.0M35.7M
Net income-19.5M-43.8M-65.7M-48.3M-75.7M-71.6M-65.9M-28.2M197.7M146.9M
EPS (diluted)-1.61-1.91-1.45-0.89-0.88-0.51-0.33-0.130.810.60
Diluted shares----86.1M139.6M197.9M224.0M243.3M244.9M
Depreciation & amortization400K1.5M2.6M2.4M3.2M4.8M6.4M7.6M7.7M8.0M
EBITDA-16.9M-37.8M-57.7M-39.0M-61.7M-53.6M-33.0M29.2M146.7M199.4M
Gross margin40.3%-28.1%-148.4%--45.2%1.4%22.9%34.4%51.5%57.4%
Operating margin-162.6%-172.7%-354.9%-141.1%-153.8%-72.1%-25.5%8.4%32.6%37.5%
Net margin-183.1%-192.3%-387.1%-164.5%-179.4%-88.5%-42.8%-10.9%46.4%28.8%
Revenue growth+48.5%+113%-25.4%+72.8%+43.9%+91.7%+90.4%+67.6%+65.2%+19.6%
EPS growth----------25.9%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-18.3M-37.3M-62.7M-76.2M-102.0M-112.4M-59.5M8.8M118.7M50.4M
Capital spending73K2.7M2.1M3.8M12.7M13.5M13.9M4.8M8.2M22.6M
Free cash flow-18.3M-39.9M-64.8M-80.0M-114.7M-125.9M-73.4M4.0M110.4M27.8M
Stock-based pay (added back)1.3M1.6M2.2M2.7M2.9M3.5M5.2M6.2M13.6M20.0M
Free cash flow after stock pay-19.6M-41.5M-67.0M-82.7M-117.6M-129.4M-78.6M-2.2M96.8M7.8M
Buybacks-------0031.9M
Debt raised4.0M30.0M072.5M27.5M-----
Debt repaid---30.0M13.9M-----
Investing cash flow905K15.2M-2.1M-3.8M-12.7M-13.5M-13.9M-5.0M-8.6M-21.9M
Financing cash flow16.8M60.8M42.9M80.0M143.9M121.0M108.9M-39.0M-58.3M-44.0M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.3M1.6M2.2M2.7M2.9M3.5M5.2M6.2M13.6M20.0M
Stock-based pay / revenue11.7%6.9%13.1%9.0%6.8%4.3%3.4%2.4%3.2%3.9%
Operating lease cash paid----500K1.4M1.8M2.4M2.4M2.5M
Finance lease principal paid----32K34K36K17K00
Right-of-use assets---1.2M4.3M7.3M10.5M9.6M8.6M6.7M
Operating lease liabilities---1.5M4.7M8.1M11.6M10.8M9.8M7.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.